Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving carboplatin and paclitaxel together with bevacizumab may kill more tumor cells.
详细描述
OBJECTIVES: Primary I. Determine the anti-tumor activity of carboplatin, paclitaxel, and bevacizumab, in terms of progression-free survival, in patients with unresectable stage IV melanoma.
II. Determine the toxicity profile of this regimen in these patients.
Secondary I. Determine the distribution of overall survival times in patients treated with this regimen.
II. Determine the response rate in patients treated with this regimen. III. Determine the changes in blood levels of vascular endothelial growth factor in patients treated with this regimen.
IV. Determine the changes in immune homeostasis in patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed melanoma
- •Unresectable stage IV disease
- •Evidence of metastatic disease
- •Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- •No radiologically confirmed invasion of adjacent organs (e.g., duodenum or stomach)
- •No tumor invasion of major blood vessels
- •No history of primary brain tumor or other CNS disease
- •No brain metastases by MRI or CT scan
- •Performance status - ECOG 0-2
- •More than 4 months
- •Absolute granulocyte count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Hemoglobin ≥ 9 g/dL (transfusion allowed)
- •No active bleeding
- •Bilirubin ≤ 1.5 mg/dL
- •AST ≤ 3 times upper limit of normal (ULN)
- •Alkaline phosphatase ≤ 3 times ULN
- •INR ≤ 1.5 times ULN
- •PTT normal
- •No known esophageal varices
- •Creatinine ≤ 1.5 times ULN
- •Urine protein creatinine ratio ≤ 0.5
- •Urine protein < 1 g/24-hr urine collection
- •No New York Heart Association class II-IV congestive heart failure
- •No serious cardiac arrhythmia requiring medication
- •No myocardial infarction within the past 6 months
- •No unstable angina within the past 6 months
- •No clinically significant peripheral vascular disease
- •No uncontrolled hypertension (i.e., blood pressure ≥ 150/90 mmHg despite antihypertensive therapy)
- •No clinically significant stroke within the past 6 months
- •No deep vein thrombosis within the past year
- •No other vascular abnormality
- •No pulmonary embolus within the past year
- •No history of abdominal fistula
- •No gastrointestinal perforation
- •No intra-abdominal abscess within the past 4 weeks
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- •No other pathological condition that would confer a high risk of bleeding
- •No active infection requiring parenteral antibiotics
- •No serious nonhealing wound (including wounds healing by secondary intention), ulcer, or bone fracture
- •No peripheral neuropathy ≥ grade 2
- •No history of allergic reaction attributed to compounds of similar chemical or biological composition to the study drugs
- •No uncontrolled seizures
- •No other uncontrolled illness
- •No significant traumatic injury within the past 4 weeks
- •No prior antivascular endothelial growth factors (VEGF), including any of the following:
- •Bevacizumab
- •VEGF Trap
- 另有 15 项未显示
排除标准
- 未提供
研究组 & 干预措施
Treatment (carboplatin, paclitaxel, bevacizumab)
Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: carboplatin (Drug)
Treatment (carboplatin, paclitaxel, bevacizumab)
Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: paclitaxel (Drug)
Treatment (carboplatin, paclitaxel, bevacizumab)
Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: bevacizumab (Biological)
Treatment (carboplatin, paclitaxel, bevacizumab)
Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Progression free survival
时间窗: Time from registration to documentation of disease progression, assessed up to 8 weeks
Constructed using the properties of the binomial distribution. Estimated using the Kaplan-Meier method.
次要结局
- Confirmed tumor response (complete response or partial response)(Up to 5 years)
- Clinical response rate(Up to 5 years)
- Overall survival(Time is defined as the time from registration to death due to any cause, assessed up to 5 years)